Athens, 19 February 2025: INTEGRIS Pharma, a Greek pharmaceutical company, and ALTRAZEAL LIFE SCIENCES, a US-based medical technology company, are pleased to announce the expansion of their successful collaboration. Building on their existing partnership in Greece, Cyprus, Bulgaria, and Malta, INTEGRIS Pharma has secured the exclusive distribution rights for Altrazeal^® (Transforming Powder Dressing™) in 32 additional European countries, including Germany, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Portugal, Sweden, Hungary, Austria, Denmark, Finland, Slovakia, Ireland, Croatia, Lithuania, Slovenia, Latvia, Estonia, Luxembourg, Serbia, Switzerland, Ukraine, Norway, Bosnia and Herzegovina, Moldova, Albania, North Macedonia and Belarus, as well as in Turkey, Israel and Azerbaijan.

Altrazeal^® (Transforming Powder Dressing™) is a revolutionary extended-wear wound management solution suitable for use with a wide range wounds. Backed by a substantial body of clinical studies^[1], Altrazeal’s advanced formulation, makes it suitable for management of various etiologies, including traumatic wounds and burns, surgical wounds and chronic ulcers of various types, including pressure ulcers, diabetic foot ulcers, vascular ulcers, and other lower limb ulcers, as well as wounds in immunocompromised patients.

Dr. Charalampos Therianos, Chief Executive Officer of INTEGRIS Pharma, stated:
“We are thrilled to expand our partnership with Altrazeal Life Sciences. This agreement enables us to bring the ground-breaking and patented technology of Altrazeal® to the European markets. By providing healthcare professionals with an advanced solution for wound and ulcer management, we are committed to improving patient care and enhancing the quality of life for thousands of individuals.”

Ms. Vaidehi Shah, Chief Executive Officer of Altrazeal Life Sciences, commented:
“Expanding our partnership with INTEGRIS Pharma marks a significant step toward establishing Altrazeal® as a global standard in wound care. Their dedication to quality and innovation will play a crucial role in increasing patient access to this advanced technology across Europe.”

About Altrazeal^® (Transforming Powder Dressing™)
Altrazeal^® is a patented, amorphous dressing comprising primarily of methacrylate-based polymers similar to those used in contact lenses. Upon hydration, its granules aggregate to form a moist, oxygen permeable matrix that conforms to the wound bed. The matrix protects the wound from exogenous bacteria while allowing excess exudate to flow through it via vapor transpiration to create an optimal environment for wound healing. As the wound heals, the Altrazeal^® matrix dries and flakes off.

Altrazeal^® enables extended wear time of up to 30 days, allowing the wound to heal without disturbing the wound bed with frequent dressing changes. It is particularly effective in the management of complex, painful, and difficult-to-dress wounds where recurrent dressing changes can aggravate pain and increase wound exposure to contamination.

For more information about Altrazeal^®, please visit https://altrazeal.com

Sources

1. [1] List of Altrazeal® clinical trials (available at www.altrazeal.com)

1. • Atypical Wounds (https://altrazeal.com/atypical-2/)

1. • Burns (https://altrazeal.com/burns/)

1. • Colorectal (https://altrazeal.com/colorectal/)

1. • Diabetic Foot Ulcers (https://altrazeal.com/diabetic-foot-ulcers/)

1. • Pediatric (https://altrazeal.com/pediatric/)

1. • Pressure Injuries (https://altrazeal.com/pressure-injuries/#NOPE)

1. • Skin Graft Donor and Recipient Sites (https://altrazeal.com/skin-graft-donor-and-recipient-sites/)

1. • Surgical (https://altrazeal.com/surgical/)

1. • Trauma (https://altrazeal.com/trauma/)

1. • Vascular Ulcers (https://altrazeal.com/vascular-ulcers/)